RP-HPLC-DAD metoda za određivanje olmesartan medoksomila kao čiste supstancije i u tabletama izloženih razgradnji [PDF]
, 2010 A simple, sensitive and precise RP-HPLC-DAD method was developed and validated for the determination of olmesartan medoxomil (AT-II receptor blocker) in the presence of its degradation products.
C. Mustafa +16 more
core +2 more sources
Current Therapeutic Research, 2014 Background: Olmesartan is an angiotensin II receptor antagonist and is effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricemic agent for the treatment of hyperuricemia and gout. Objective: The
Kun-Yan Li, PhD +6 more
doaj +1 more source
Is early and fast blood pressure control important in hypertension management? [PDF]
, 2018 Control of blood pressure (BP) in hypertension is recognized as a key measure in the management of cardiovascular (CV) risk and is a cornerstone of preventive strategies. It is not defined, however, whether an initiation of the antihypertensive treatment
Gallo, Giovanna +2 more
core +1 more source
A case of acanthosis nigricans in a HIV-infected patient [PDF]
, 2020 Background: To date, very little information is available concerning the relationship between acanthosis nigricans (AN) and infection with human immunodeficiency virus type 1 (HIV-1).
De Vincentiis, Ludovica +5 more
core +1 more source
Olmesartan-induced enteropathy
BMJ Case Reports, 2018 Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. We describe a 68-year-old Caucasian woman with a history of hypothyroidism and hypertension who presented to our hospital with recurrent episodes of acute intermittent diarrhoea ...
Nirmal K Onteddu +3 more
openaire +3 more sources
Journal of Pharmacological Sciences, 2010 Clinical studies have shown that angiotensin-receptor blockers (ARBs) reduce the risk of cardiovascular diseases in hypertensive patients. It is assumed that the reduction of the risk by ARBs may be attributed in part to the inhibition of angiotensin II (
Yoji Kyotani +6 more
doaj +1 more source
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers : a randomized study [PDF]
, 2013 Background: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are renoprotective but both may increase serum potassium concentrations in patients with chronic kidney disease (CKD).
A Mimran +52 more
core +1 more source
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension [PDF]
, 2017 The efficacy and safety of azilsartan medoxomil (AZL-M) were evaluated in African-American patients with hypertension in a 6-week, double-blind, randomized, placebo-controlled trial, for which the primary end point was change from baseline in 24-hour ...
Bakris, George L. +9 more
core +2 more sources
The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases [PDF]
, 2019 Inflammation is a normal part of the immune response to injury or infection but its dysregulation promotes the development of inflammatory diseases, which cause considerable human suffering.
Avan, Amir +5 more
core +1 more source
Case report of an exercise training and nutritional intervention plan in a patient with A350P mutation in DES gene. [PDF]
, 2020 Performing a supplementation intervention with creatine and protein, in conjunction with low-intensity endurance and resistance exercise is safe and has a positive effect on the quality of life in a patient with ...
Baar, Keith +3 more
core +1 more source